Summary:
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory
Patients with COVID-19
Each patient must meet the following criteria at screening or enrollment to be
eligible for this study:
1. First onset of COVID-19 symptoms <7 days at randomization, symptoms
such as fever and/or chills, fatigue, muscle or body aches, headache, new
loss of taste or smell, sore throat, congestion or runny nose, nausea or
vomiting, and diarrhea.
2. Have a positive SARS-CoV-2 Reverse Transcription-Polymerase Chain
Reaction (RT-PCR) test using an appropriate sample such as nasopharyngeal (NP), nasal, oropharyngeal, or saliva within 72 hours
prior to randomization. A historical record of a positive result from a test
conducted ≤72 hours prior to randomization is acceptable.
3. Male or female patients ≥18 years of age at the time of signing
informed consent.
Qualified Participants May Receive:
Up to $1500 for time and participation